BPC-157 & TB-500: The Truth About the Wolverine Stack

Wolverine stack. If you spent more than 10 minutes on fitness, Tik Tok, a biohacking podcast, or god forbid, a longevity subreddit, you've likely heard of the so-called Wolverine stack. BPC-157 and TV500. Two peptides that the internet has collectively decided can heal everything from a torn ACL to perhaps a broken heart, maybe even a dishwasher, but I have not confirmed that one yet. Now, they call this the Wolverine stack because supposedly these two compounds together give you Wolverine like healing abilities. And look, I get the appeal. As an elder millennial knocking on the door of 40, who doesn't want to recover like a Marvel character? But let me be very clear about something right now. These two peptides may be called the Wolverine stack, but they are not going to make you look like Hugh Jackman and Logan. You know what it takes to make you look like Hugh Jackman and Logan? Tren. Of course, it's Tren. I mean, look at him. How could it ever be anything else besides Tren? Now, if you haven't seen our video on Trenalone, go click the link right now. We covered that compound extensively and let me tell you the side effects are a lot more colorful there than anything we're covering today. Now, before we go any further, I need to ask you something and I want you to drop your answer in the comments down below. Here's the question. Have you ever used BPC57, TB500, or any other peptide? And if so, what was your experience? Did it actually work, or did you just convince yourself it worked because you spent $300 on a vial from a website with a name like peptidbros.io on it? Drop your answer down below. I genuinely want to know. And your engagement helps the algorithm show this video to more people who need actual science instead of just bro science. What's up, guys? I'm Dr. Alex. I'm a board-certified urologist and fellowship trained men's health specialist. I run the men's health center at Urology of Indiana, and I make videos on this channel where I take the stuff that the fitness and wellness community is obsessed with and run it through the ringer of actual published medical literature with a sprinkling of sexual health and boner jokes mixed in. It's the Lord's work. And today, BPC57 and TV500 are in the hot seat. Now, why should you care? Because these are the two most widely used, widely discussed, and widely misunderstood compounds in the entire peptide space. People are injecting these things, taking them orally, rubbing them on their skin, and in some cases combining them in ways that literally have zero published data behind them. I'm counting down the days until I see some zoomer try and vape these things on TikTok as an asthma cure. Meanwhile, Joe Rogan is out here telling millions of people that BPC57 cured his elbow tendonitis in two weeks, and half of Instagram is selling them as research chemicals not for human consumption with a wink and a nudge. Comment down below if you too selfidentify as a large lab rat with a stimulant dependency. I see you. All right, so let's do what we always do on this channel. Let's look at the actual science. What do these compounds do? Where do they come from? And is there any real evidence? Or is this the peptide version of putting crystals on your nightstand and hoping for the best? Let's start at the beginning. BPC-157 stands for body protection compound 157. And yes, that's its real name. Not exactly subtle branding. It's a synthetic peptide made up of 15 amino acids with a molecular weight of about 1,419 dolton. Its amino acid sequence is if you're the type of person who finds that interesting. And if you are, congratulations. You have my kind of tism. Here's where it came from. In the late 1980s and early 1990s, a research group at the University of Zagreb in Croatia led by a pharmacologist named Dr. Pedrag Sikitch was studying the protective properties of human gastric juice. They noticed that certain compounds of stomach acid seem to protect the gastrointestinal lining from injury and promote healing. This makes sense if you think about it. Your stomach is basically a bag of hydrochloric acid that somehow doesn't digest itself. There's clearly some protective machinery at work or black magic. I'm a urologist and therefore just a glorified penis mechanic. So I'm doing my best here. Dr. Sikarich's team isolated a protein that they called body protection compound from gastric juice and then synthesized a stable 15 amino acid fragment of that protein. That fragment became BPC57. And the earliest PubMed entry dates all the way back to 1992. And since then, Dr. Sikri has published over 150 papers on the compound. And I do want to note something here that we need to come back to. The vast majority of BPC57 research, over 80% of it, comes from the single research group in Zagreb. It's not disqualifying, but it's worth keeping in mind. TB500, however, is a different animal. Pun somewhat intended. Its full parent compound is thyosin beta 4, and it's a 43 amino acid protein that was discovered in the 1960s. The story starts in the Albert Einstein College of Medicine in New York, where a post-doal researcher named Alan Goldstein working in the laboratory of Abraham White was studying the thymus gland. Quick anatomy refresher. The thymus sits behind your breast bone above your heart and it's essentially boot camp for your tea cells. Your immune system special forces train there. In the early 1960s, scientists were just then figuring out that the thymus wasn't a vestigial organ and was actually the master gland of adaptive immunity. So in 1966, Goldstein and White published their first paper naming these thymus derived proteins thymusins. And by the 1970s, Goldstein's team at the University of Texas Medical Branch in Galveston had isolated and characterized individual thymosins from calf thymus tissue, including thyosin beta 4 in its complete amino acid sequence was published in 1981. Now, here's the cool part. Everyone initially thought thyosin beta 4 was purely an immune system molecule, but then it turned out to be everywhere in blood platelets, skin cells, muscle tissue, the brain, and basically anywhere the body needs to repair itself. Its primary job is to regulate actin, one of the most fundamental structural proteins in every cell of your body. Actin is what gives your cells their shape, lets them move, and drives tissue repair. TB500 is the synthetic version of the active region of thyosin beta 4. It's a seven amino acid peptide with a sequence of a corresponding to the chunk of thyosin beta 4 that research believe is responsible for most of its biologic activity. Think of TV500 as the cliffnotes version of the full protein. So, in 1974, a 5-year-old girl named Heather became the first human ever treated with thyosin. She had a non-functioning thymus gland and was critically ill. And the treatment successfully boosted her immune system and saved her life. So, this isn't exactly fringe science. There have been serious medical applications. But there is a massive gap between discovered by serious immunologists at Albert Einstein College of Medicine and being sold on a website called gainspeptides.com to guys who want to heal their torn rotator cuff faster. We need to talk about how we got from A to B. All right, let's talk biochemistry. And I promise I'll try to make this as painless as possible. Think of this as pharmarmacology class, but with better jokes and no final exam. Now, if you actually talked to girls in high school, and therefore complex and pedantic explanations of biochemical pathways aren't your bag, just skip to the time code that Ronic totally won't forget to put down here. Just make sure to hit the like and subscribe buttons first. BPC57 appears to work through multiple signaling pathways, which is part of why it's so intriguing and also why it's so hard to pin down. So, let's talk about those. First, and probably most important is the nitric oxide system. BPC57 activates something called the CRC cavalin 1 ENOS pathway. In English, it increases nitric oxide production in your blood vessels. Nitric oxide is a vasoddilator. It opens up blood vessels and improves blood flow. And as a penis doctor, consider me intrigued. More blood flow means more delivery of oxygen and nutrients to damaged tissue and its effect on this pathway was first published as recently as 2020 in the journal scientific reports by Shay and colleagues. Now the second pathway is angioenesis. BPC57 upregulates veg FR2 which is a vascular endothelial growth factor receptor 2. This triggers the growth of new blood vessels. More vessels generally means more healing capacity. It activates the veg FR2 AKT enos signaling cascade which drives indothelial cell proliferation migration and tube formation. And this was published as recently as 2017. Shout out to anyone who had to actually learn MLA style bibliography formatting in elementary school. Also, friendly reminder, it's time for your colonoscopy. Now, third is the ERK1/2 pathway. BPC57 upregulates VEGFA expression and activates ERK12 along with downstream transcription factors COS, CUNE and EGR1. These are key molecules in cell growth, migration and blood vessel formation. Fourth is the FAK paxillan pathway in tendon fibroblast specifically BPC57 promotes cell survival under oxidative stress, enhances migration and activates focal adhesion, kynise and paxillin. This drives actin cytokeleton reorganization, basically helping repair cells get to where they need to go. Chang and colleagues published this back in the journal of applied physiology in 2011. So if you put all of this together, BPC57 reveals itself to be a multiaway compound that tells your body to make more blood vessels, send more blood to the injury, help repair cells survive and migrate, and then rebuild the tissue architecture. That is incredibly compelling on paper. TB500 on the other hand works through a fundamentally different but complimentary mechanism. Its primary job is actin regulation. Thyosin beta 4 binds to Gactin which is the monomeic form of actin in a 1:1 ratio. By sequestering these actin monomers, it regulates the balance between free actin and polymerized actin filaments. This controls cellular motility, development, and differentiation. A 2025 study in investigative opthalmology and visual science even engineered tandem thyosin peptides that bind two of the Gactum molecules simultaneously showing enhanced bioactivity in cardiac models. Recombinant human thyosin beta 4 activates the ERB2/rath 1 signaling pathway which suppresses cardiammyioite apoptosis basically preventing heart cells from dying after injury. And here's a really interesting recent finding. TB500's wound healing activity may actually be driven primarily by its metabolite AC-LK rather than TB500 itself. A 2024 study in the Journal of Chromatography found that only this breakdown product showed significant wound healing activity in fibroblast assays. So you might be injecting TB500, but what's actually doing the heavy lifting is the piece your body breaks it down into. That's got to be humbling for any molecule. Okay, okay, okay, enough biochemistry. Does any of this actually work in humans? And unfortunately, that's where the record scratches. For BPC57, the pre-clinical data is legitimately impressive. In rodent models, this compound accelerates healing in basically every tissue you can think of. GI ulcers, tendon injuries, muscle tears, bone fractures, skin wounds, even nerve damage, and traumatic brain injury. It preserves corial transparency, normalizes intraoccular pressure and glaucoma models, prevents thrombosis, and counteracts Parkinson's like and Alzheimer's like symptoms. and rodents. The list is almost suspiciously long. But when you look for human clinical data, it's thin. Like really thin. Now, there are references to phase 2 trials for ulcerative colitis and multiple sclerosis conducted through PVA, a Croatian pharmaceutical company. These trials apparently showed no toxicity. But here's the thing, the detailed results have never been published in peer-reviewed literature. Read that again. That that was for me. These results have never been published in the peer-reviewed literature. Phase two trials were conducted and the results were never fully published. Uh that's that's not great. Now there was a 2024 pilot study on interstatial cyitis which is a bladder irritation syndrome where 12 women received intravesical BPC57 injections. 10 of those 12 reported complete symptom resolution which sounds amazing until you realize the study was uncontrolled unblinded conducted at a single private clinic and relied on subjective self-reported symptom improvement. That's not how you prove something works. That's how you write an optimistic case series. Speaking of which, there's also a case series on intraarticular knee injections showing pain improvements. But again, no controls, tiny sample size, and no objective outcome measures. Methodologically, it's not solid evidence. And for TB500 specifically, there are zero published human clinical trials. Not one. Now, the parent compound thymus and beta 4 has better human data. RGN259, which is a 0.1% thymus and beta 4 eye drop, showed statistically significant improvements in a phase 2 randomized double mass placeboc controlled trial for severe dry eye disease. We're talking a 35% reduction in ocular discomfort and a 59% reduction in corial staining. That's real data. And that was published back in 2015. And there's a randomized placeboc control double blind trial of recompetent human thymus and beta 4 in 96 heart attack patients. and this showed reduced infar areas in a treatment subgroup at 90 days published in the journal cardiovascular research in 2025. Unfortunately, the overall group comparison didn't reach statistical significance. So, here's an honest summary. We have extensive and internally consistent animal data, a handful of small and methodologically limited human studies for BPC-157, zero human trials for TB500, and some encouraging but early stage clinical data for the full thyosin beta 4 protein in eye disease and cardiac repair. Meanwhile, you animals are combining these two compounds at doses extrapolated from rat studies and injecting them daily. Some of those people are probably watching this video right now, and welcome. You're loved here. I'm not here to judge you. I'm here to make sure that you understand what the evidence actually says. Oh, and for the record, that whole Wolverine stack combination, the theoretical rationale for the synergy is actually pretty reasonable. BPC57 handles the vascular side, bringing blood supply and supporting vessel growth. TB500, on the other hand, handles the cellular side, promoting cell migration, tissue remodeling, and some anti-inflammatory effects. And in tissue healing, you need both blood supply and cellular repair. It's like a construction project. BPC-157 builds the roads and TE500 sends in the workers. But how many published studies have directly evaluated this combination in any model system? Zero. Zero studies. Not one. The Wolverine stack is an entirely theoretical construct. And it could be brilliant. It could also be two things that interfere with each other in ways nobody has studied. We just don't know. And yet, you can buy premixed vials of both on websites that also sell peptide mixing kits and offer discount codes from fitness influencers. God, I love the internet. And here's a question that I get asked constantly. If BPC157 and TB500 are so promising, why hasn't a pharmaceutical company just developed them into actual FDA approved drugs? Seems like a billion-dollar idea, right? But the answer involves something you might not expect. The United States Supreme Court. In 2013, the Supreme Court decided a case called Association for Molecular Pathology versus Myriad Genetics. The case was about Myriad's patents on the Brocoa 1 and Broa 2 genes. You know, breast cancer genes. In a unanimous decision, the court ruled that naturally occurring DNA segments are products of nature and therefore can't be patented merely because they've been isolated. Justice Clarence Thomas wrote the opinion stating that laws of nature, natural phenomena, and abstract ideas are the basic tools of scientific and technological work and lie beyond patent protection. The court explicitly said that products of nature are not created and that manifestations of nature are free to all men and reserved exclusively to none. Now, that seems like a good thing until you realize that BPC57 is derived from a naturally occurring protein in human gastric juice. Thymos and beta 4 is a naturally occurring protein found throughout the human body. Under the principles established in Myriad and the earlier Mayov Prometheus decision, patenting these naturally occurring peptides, even in isolated form, faces serious legal hurdles. And here's why that matters commercially. Drug development in the United States is obscenely expensive. We're talking hundreds of millions of dollars or billions just trying to bring a drug through phase one, phase two, and three trials. Then you got to manufacture it at scale. then you got to get FDA approval. Pharmaceutical companies do this because they get a patent and usually 20 years of exclusivity, which lets them recoup their investment and then some. But if you can't patent the molecule itself, if anyone can make generic BPC 157 the day after you spend 800 million proving it works, that financial incentive totally evaporates. No rational pharmaceutical executive is going to spend that kind of money developing a product that any compounding pharmacy or research chemical company can immediately copy. This is the fundamental paradox of peptide therapeutics. The closer a compound is to something your body naturally produces, the harder it is to patent, and the less likely it is that anyone with deep pockets would ever fund the clinical trials necessary to prove that it works. It's not a conspiracy. It's basic economics combined with patent law and probably also some conspiracies. Now, there are some workarounds. You can patent specific formulations, delivery mechanisms, or novel synthetic analoges. That's essentially what Regenerex did with RGN259 for the thymosin beta 4 ey drops. But for BPC 157, with its origins in a single Croatian research group and patent applications dating all the way back to the late 1980s, the commercial development pathway is complicated to put it diplomatically. So, here we are stuck in this limbo where the compounds are potentially promising, but the economic and legal framework doesn't incentivize the kind of rigorous large-scale clinical trials we need. And in that vacuum, the gray market has thrived. But we've heard what's good about BPC57 and TB500. Let's talk about what could potentially go wrong. So, what are the potential side effects with these two compounds? In the published pre-clinical literature, BPC57 has an almost eerily clean safety profile. Safety evaluations in mice, rats, rabbits, and dogs revealed no serious toxicity, no genotoxicity, and no embryo fetal toxicity. Researchers literally could not find a lethal dose, and the LD1 was never reached. The only noted effects were some mild local irritation at injection sites and a transain decrease at very high doses in dogs that resolved on its own. That means the kidneys may have actually gotten healthier, but we just don't know enough to say that for sure. Now for TB500, the metabolic data shows rapid metabolism in rats with primary metabolites detectable up to 72 hours with urinary excretion and no cytotoxicity. Now anecdotally, users report headaches, swelling at injection sites, nausea with oral administration, and then hot flashes from the vasoddilatory effects of nitric oxide release. These are generally mild and self-limiting. But here's something that deserves attention. Both BPC 157 and TV500 promote angioenesis, the growth of new blood vessels. That is exactly what makes them potentially useful for healing. But angioenesis is also a hallmark of cancer progression. It's a stretch, I know, but tumors need blood supply to grow. And that's the entire basis for anti-angioenic cancer drugs like Bevvisumab. Now, does BPC57 cause cancer? We have zero evidence saying it does, but we also don't have enough long-term safety data in humans to say that it doesn't. This is a legitimate concern that deserves rigorous study, not to be dismissed with a just ah the rats were fine. Now, Dr. Sikerich's group has actually addressed this, claiming that BPC57 presents prominent anti-tumor potential, but independent verification of this claim is essentially non-existent and the absence of evidence is not the same as the evidence of absence or evidence of my involuntary absence through both high school and college. All right, so let's talk about the elephant in the room that should concern everyone, regardless of how you feel about the compounds themselves. Because BPC57 and TB500 are not FDA approved, they are not manufactured under good manufacturing practice standards. They come from unregulated labs, often overseas, and are sold as research chemicals, not for human consumption. Sure, Jan. Sure. Independent lab testing of gray market peptides has found some genuinely alarming results. Products contaminated with arsenic and lead, sometimes at 10 times the acceptable limit for injectable drugs, bacterial endotoxins that could cause sepsis, products with the wrong amino acid sequence entirely, purity levels as low as 5 to 75% filled with unknown chemical byproducts. Let me say that again. Some of these products are 5% pure, which means 95% of what you're injecting into your body is something else, something unknown. And you're doing this based on the recommendation from a guy on a podcast whose sponsors include a mattress company and perhaps even more damning AG1. The video's up here. I say this because I love you. Now, water, the World Anti-Doping Agency, basically the wet blankets of professional sports, currently lists both these compounds as prohibited substances. BPC57 falls under the S0 category of unapproved substances. Athletes who test positive face suspension. Interestingly, the Department of Defense also specifically warns against use by military service members. You'd think that they'd want to fund research on compounds that might help healing, but I'm just a talking head on the internet. So, to summarize the risk picture, the compounds themselves have a relatively clean preclinical safety profile, but virtually no long-term human safety data. The theoretical cancer risk from a pro-angioenic activity is indeed a significant question, and the products most people are using may contain dangerous contaminants, incorrect ingredients, or unknown impurities. It's a real choose your own adventure situation with some of those adventures potentially ending at an emergency room near you. All right, so I've spent a lot of time telling you guys about the limitations and risks, but let me be fair and lay out why people use these compounds and why their enthusiasm is understandably justified. The preclinical evidence for BPC57 and muscularkeeletal healing is genuinely impressive. In rodent models, it consistently accelerates the healing of tendons, ligaments, muscles, and bones with improved biomechanical properties and faster functional restoration. If you're a rat with a torn Achilles tendon, BPC57 is the best thing that ever happened to you. Its gastrointestinal effects are equally noteworthy. It heals ulcers, protects mucosal integrity, reverses short bowel syndrome in animal models, and counteracts the GI damage caused by incaids. Given that a huge number of people take ibuprofen and other insaids regularly, a compound that could potentially protect them against GI side effects is really intriguing. It also has neuroprotective properties in animal models, showing benefit in traumatic brain injury, spinal cord compression, and even neurodeenerative disease models. It maintains corial transparency, helps with glaucoma, and accelerates skin wound healing. And perhaps most importantly for the healing applications, BPC57 is effective across multiple routes of administration, oral, injectable, and even topical. And it works at very low doses in the microgram per kilogram range. Its stability in gastric juice for over 24 hours makes oral dosing viable, which is unusual for peptides. Most peptides get destroyed in the stomach. This one was literally born there. I was born in the darkness. TB500's appeal is its role in cellular repair and tissue remodeling. By regulating actin dynamics, it influences cell migration which is critical for wound healing. Cells need to physically move to injury sites and TV500 facilitates that process. Its cardiac data is really compelling and mouse models thymus and beta 4 treatment prevented cardiac dysfunction and fibrosis at 28 days after eskeeia reprofusion injury reducing infark size and improving cardiac function. The C terminal AES tetropeptide enhanced myasy survival and increased coronary vessel growth. For you debball lovers out there, the hpata protrotective effects are also notable. Exogenous thyosin beta 4 significantly reduce liver injury in animal models of chemical hepattoxicity, suppressing inflammation and oxidative damage. And the dryey data from the phase 2 RGN259 trial is the closest thing we have to validated clinical evidence for any of these compounds. significant improvements in symptoms and clinical measurements in a proper randomized controlled trial. So, if you're considering trying these compounds, and I know some of you already are because I can already hear the keyboards clicking, here's what you should know. Number one is that source quality matters more than anything else. If you're going to use these things, at minimum, ensure the product has a certificate of analysis from a third-party lab showing purity, amino acid sequence confirmation, and the absence of endotoxins and heavy metals. If a seller can't provide that, walk away. actually run. Unless you want these because you torn your Achilles, in which case you may need to hobble. Whatever works. The second thing worth considering is that the pharmacocinetics of BPC57 suggest a half-life of less than 30 minutes after injection with intramuscular bioavailability of only 14 to 19% in rats. That means you need to think carefully about dosing frequency and route. A lot of the protocols floating around online are based off of vibes, not pharmarmacology. The third issue is that there is no established human dose for either compound. Everything is extrapolated from animal studies and alometric scaling from rats to humans is an imprecise science at best. Fourth is that if you're a competitive athlete, these are prohibited substances. So, USADA, the DoD, they're all watching. Don't risk your career on compounds that haven't even been proven to work in humans. And number five, talk to your doctor. And I mean an actual doctor, not a concierge medicine doc who's moonlighting as an influencer with a discount code. get an objective medical opinion from someone who doesn't have a financial interest in your decision. So, all right, let me give you my honest conclusion. No hype, no fear-mongering, just my honest assessment as a physician who has spent considerable time reviewing this literature and hurting myself in the gym. BPC57 and TB500 are genuinely fascinating compounds with extensive pre-clinical evidence supporting their regenerative properties. The mechanisms are well characterized and biologically plausible, and the breadth of positive animal data across nearly every organ system is remarkable. I'm not going to sit here and pretend that this body of research isn't interesting and isn't promising because it is. But interesting pre-clinical data is not the same thing as proven clinical efficacy. We need to be intellectually honest about where we stand. For BPC57, we have over 150 animal studies, a few tiny uncontrolled human studies, and some unpublished phase 2 trial data. And for TB500, we have zero human clinical trials. And for the combination, the Wolverine stack, we have zero studies of any kind. And the publication bias concern is real. When over 80% of your published literature comes from a single research group with consistently positive results and zero published negative or null findings, that should give you pause. It doesn't mean the research is wrong, but independent replication is one of the pillars of science, and that one hasn't been adequately fulfilled here. Not not yet, anyways. Now, does the lack of reported toxicity mean these compounds are safe? Not necessarily. But let me put this into perspective. The absence of reported toxicity in extensive pre-clinical testing is actually a pretty good starting point. That's more safety data than has existed for the majority of compounds entering human trials. If we're being honest, it's a lot better than a lot of FDA approved drugs that already have side effect profiles that make BPC-157's pre-clinical record look like a spa day. Have you ever read the prescribing information for methtraate or isotenino or any biologic? Those are approved drugs and their side effect lists read like a Stephen King novel. So the real question isn't are these dangerous, it's do we have enough information to know? And the answer is right now unfortunately no, we don't. And that uncertainty cuts both ways. So here's what I think needs to happen. These compounds deserve rigorous independent NIH level funding for proper clinical trials. Not industry funded trials, not single-c center pilot studies from the same group that discovered them, but large-scale multic-center randomized controlled trials with independent oversight. The patent law problem that I described earlier means pharmaceutical companies may never foot the bill. And that's where public funding becomes essential. We invest billions of taxpayer dollars into biomedical research every year. Some of that should go towards investigating compounds that millions of people are already using so we can actually tell them whether it's helping, hurting, or doing nothing. Because here's the thing, the peptide genie is out of the bag. People are using BPC157 and TV500 right now in huge numbers. Pretending that's not happening or just saying don't do it because it's not FDA approved isn't a strategy. It's burying your head in the sand. So yeah, we need data, real data from real trials and real humans. And I say this as someone who believes these are promising compounds with significant potential, not just to heal injuries faster, but to help us live not just longer, but better. Better recovery from surgery, better outcomes after heart attacks, better healing for the tens of millions of Americans dealing with chronic muscularkeeletal pain, better healing for me, who apparently needs six weeks of physical therapy just cuz I slept on my neck wrong. But promise and proof are two different things. And until we bridge that gap with proper clinical evidence, I'm going to keep doing what I do. Giving you the facts, the limitations, and enough information for you to make your own informed decision. That's what this channel is all about. Not telling you what to do, giving you the tools to decide for yourself with actual science and occasionally some jokes about Gorilla Mind energy drinks and zens. Because if I can't have fun with this, what's even the point? So, if you found this video helpful or even just entertaining, smash that like button and hit that hype button if you see it down there anywhere. And yes, I know smash the like button is the most cliched thing on YouTube, but it genuinely helps. The algorithm sees likes and goes, "Oh, people actually watch this guy talk about peptide biochemistry for 30 minutes. Maybe I should show it to more people." It's how this works. I don't make the rules. I just exploit them. Subscribe if you haven't already. I put out evidence-based content on men's health, fitness, and topics that most doctors wouldn't touch on YouTube, like my nicotine habit, because most physicians think that making YouTube videos is beneath them. And most fitness influencers don't actually read the studies they site. I do both. You're welcome. And most importantly, drop a comment below answering the question from the beginning. Have you used BPC157 or TV 500? What was your experience? I want to hear real stories, not what you read on a Reddit thread at 2 a.m. while taking your six white monster in third Zen of the evening. Although, if that is your experience, tell me that, too. I'm all about normalizing my own poor choices. And if you want to see our deep dives on other compounds, check out our video on trembolone, which is basically the antiBBc157 in terms of risk benefit ratio. Also, check out our videos on testosterone and dietary protein, creatine, and all the other stuff we covered on this channel. Share this video with someone who needs to hear it, especially if they're about to order peptides from a website that accepts cryptocurrency and has an FAQ section that includes the question, "Is this legal?" I'm Dr. Alex. Stay curious. Stay skeptical and stay away from any website that sells injectable compounds and also sells gym tank tops. Unless, of course, it's my merch, which Ronic insists he's working on. Proceed accordingly.